Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials
- Design
- Meta-analysis · Intermediate outcome
- Match to healthy normal-weight adults aged 55–75
- Population unclear[Auto] Synthesis; population mix not determinable from abstract. Review the included-study populations.
- Could weight loss explain it?
- Unknown[Auto] Not addressed in abstract.
- Study tier
- Study tier 2[Auto] Systematic review/meta-analysis of randomized trials (auto-provisional; heterogeneity and included-study quality not assessed).
- Assessment
- Version 3 · Checked against the source by AI · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
A meta-analysis of randomized trials found retatrutide lowered systolic blood pressure (by about 6.8 mmHg) and diastolic blood pressure (about 2.5 mmHg) and reduced total cholesterol, LDL-C and triglycerides, but had no effect on HDL-C (WMD -0.01 mg/dL, 95% CI -1.30 to 1.27, p = 0.98). These are blood pressure and lipid risk markers, not heart attacks or strokes.
01Findings
What the study reported
- Drugs
- Retatrutide
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Not extracted
Who was studied
Study quality details
- Study design
- Meta-analysis
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- intermediate
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- UNKNOWN
- Statistical precision
- CI reported: 95% CI: - 8
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Ethical approval: Not applicable. Data availability statement: The data underlying this article are available in the article and in its online supplementary information.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[INTRODUCTION] It has been reported that glucagon-like peptide-1 (GLP-1) agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists exert beneficial effects on blood pressure and lipid profile. However, the impact of triple agonist retatrutide on these metabolic markers remains to be elucidated. [AIM] This meta-analysis aims to investigate the effect of retatrutide on blood pressure and lipid levels through a meta-analysis of randomized controlled trials. [METHODS] The search process was performed in PubMed, Cochrane Library, Scopus, and ClinicalTrials.gov databases using MeSH terms and keywords. For meta-analysis, a random-effects model and the generic inverse variance method were used. [RESULTS] The meta-analysis showed that retatrutide significantly decreases systolic blood pressure (WMD: - 6.79 mmHg, 95% CI: - 8.36, - 5.23, p < 0.0001, I2 = 20%) and diastolic blood pressure (WMD: - 2.46 mmHg, 95% CI: - 3.25, - 1.67, p < 0.0001, I2 = 0%). Furthermore, a significant reduction in the levels of total cholesterol (WMD: - 21.88 mg/dL, 95% CI: - 27.79, - 15.97, p < 0.0001, I2 = 84%), LDL-C (WMD: - 13.10 mg/dL, 95% CI: - 16.10, - 10.10, p < 0.0001, I2 = 47%), and triglycerides (WMD: - 40.90 mg/dL, 95% CI: - 48.50, - 33.30, p < 0.0001, I2 = 53%) was observed after retatrutide treatment. However, this triple hormone receptor agonist had no significant effect on HDL-C concentrations (WMD: - 0.01 mg/dL, 95% CI: - 1.30, 1.27, p = 0.98, I2 = 0%). [CONCLUSIONS] The results of our meta-analysis revealed that retatrutide treatment decreases blood pressure and improves lipid profile by reducing total cholesterol, LDL-C, and triglyceride levels.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 30, 2026 | 42371360 first ingestion |